Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Maxcyte Inc (MXCT)

Maxcyte Inc (MXCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire - Mon Jan 12, 7:05AM CST

ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery,...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.2650 (+2.85%)
MaxCyte Announces Planned CFO Transition in 2026 GlobeNewswire - Wed Nov 12, 2025

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.2650 (+2.85%)
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance GlobeNewswire - Wed Nov 12, 2025

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.2650 (+2.85%)
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 GlobeNewswire - Wed Oct 8, 2025

ROCKVILLE, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.2650 (+2.85%)
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors GlobeNewswire - Mon Oct 6, 2025

ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.2650 (+2.85%)
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability GlobeNewswire - Mon Sep 22, 2025

ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.2650 (+2.85%)
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance GlobeNewswire - Wed Aug 6, 2025

ROCKVILLE, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.2650 (+2.85%)
MaxCyte Signs Platform License Agreement with Adicet Bio GlobeNewswire - Mon Aug 4, 2025

MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform to support development of Adicet’s gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE)...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.2650 (+2.85%)
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline GlobeNewswire - Thu Jul 31, 2025

ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc ., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.2650 (+2.85%)
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 GlobeNewswire - Wed Jul 9, 2025

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.2650 (+2.85%)

Barchart Exclusives

SanDisk Stock Keeps Surging. Did You Miss Your Chance to Buy? Barchart - 11 minutes ago
SanDisk's remarkable post-spinoff performance underscores its leadership in flash memory amid AI-driven demand, though lofty valuations prompt questions about future upside. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot